#jobs #lifescience Diamond Light Source: Support Scientist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Diamond Light Source: Support Scientist .
Competitive:

Diamond Light Source:
Diamond Light Source is the UK’s national synchrotron.
Didcot, Oxfordshire

from Job Search RSS https://ift.tt/2qX2Bz7

#jobs #lifescience Paramount Recruitment: Senior Software Developer – Biotechnology

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Paramount Recruitment: Senior Software Developer – Biotechnology .
Negotiable:

Paramount Recruitment:
Software Developer – Biotechnology

Paramount are working in collaboration with Genomics England as they look to grow their technical team, in order to deliver success with the 100,000 Genomes Project.
London, England

from Job Search RSS https://ift.tt/2Hq8Ph1

#jobs #lifescience RHL: Sales Manager (Cattle)

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: RHL: Sales Manager (Cattle) .
Negotiable:

RHL:
If you have had any practical experience of dairy farming through University/College or practical dairy farming work experience and have a passion for sales, then this is the job for you………… Job Title: Dairy Sales ManagerReference No: 239738 The Dairy Sa
Lancashire, England

from Job Search RSS https://ift.tt/2qYgrBf

#jobs #lifescience Paramount Recruitment: Software Developer – Biotechnology

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Paramount Recruitment: Software Developer – Biotechnology .
Negotiable:

Paramount Recruitment:
Software Developer – Biotechnology

Paramount are working in collaboration with Genomics England as they look to grow their technical team, in order to deliver success with the 100,000 Genomes Project.
London, England

from Job Search RSS https://ift.tt/2qZb5EV

#jobs #lifescience The Francis Crick Institute: Project Research Scientist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: The Francis Crick Institute: Project Research Scientist .
Competitive with benefits, subject to skills and experience:

The Francis Crick Institute:
A Project Research Scientist role is available in the Kassiotis Lab.
London (Central), London (Greater) (GB)

from Job Search RSS https://ift.tt/2HquEkK

#jobs #lifescience SRG: Stem Cell Scientist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: SRG: Stem Cell Scientist .
DOE:

SRG:
Stem Cell Scientist (16 Month Contract)Do you hold a PhD with strong skills in Stem Cell Culture and Differentiation into Neural Cells? Are you looking for an opportunity to join a small, innovative company undergoing continued success?My client based in
Cambridgeshire, England

from Job Search RSS https://ift.tt/2qZEI9h

#jobs #lifescience Paramount Recruitment: Senior Software Developer – Biotechnology

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Paramount Recruitment: Senior Software Developer – Biotechnology .
Negotiable:

Paramount Recruitment:
Senior Software Developer – Biotechnology

Paramount are working in collaboration with Genomics England as they look to grow their technical team, in order to deliver success with the 100,000 Genomes Project.
London, England

from Job Search RSS https://ift.tt/2HqgXSN

Explore the Life Sciences Corridor on Innovation Bus Tours

Visit the “Brain-Train” Cities – Boston, Braintree, Cambridge, Quincy
and Somerville

BOSTON & BRAINTREE, Mass. & CAMBRIDGE, Mass. & SOMERVILLE, Mass. & QUINCY, Mass.–(BUSINESS WIRE)–On Monday, June 4, as part of BIO 2018 and the Massachusetts Biotech
Ecosystem Tours, the Life
Sciences Corridor
, a partnership created by the mayors of Boston,
Braintree, Cambridge, Quincy and Somerville, will conduct bus tours
exploring these biotechnology hubs and several of the life sciences
companies driving innovation.

Boston will conduct two tours: one includes the South Boston
Waterfront District, and the other includes the Longwood Medical Area
and Fenway. The South Boston Waterfront District offers a dynamic mix of
opportunities and spaces, drawing on burgeoning technology, biotech and
design communities. At the heart of this area is District Hall, the
world’s first civic innovation center. This interdisciplinary community
is home to GE headquarters and MassChallenge, the most startup-friendly
accelerator in the world. Boston’s Longwood Medical and Academic Area is
a thriving community of medical, academic, research and cultural
organizations, home to over 57,000 scientists, researchers and staff,
and over 29,000 students. The LMA is one of the densest medical clusters
in the United States. The tour will include a site visit to Dana-Farber
Cancer Institute’s recently completed research facility.

The town of Braintree’s tour will highlight why two global
companies, Haemonetics and Citra Labs, chose Braintree’s proximity to
the intellectual capital of the Greater Boston area – geographic
advantages, transportation assets available for product distribution and
employee commutes are reasons for calling Braintree home.

Cambridge will conduct two tours: one includes exploration of
LabCentral Pfizer and the other includes Kendall Square MIT’s Koch
Institute. On one tour you will learn how LabCentral, a co-working
launch-pad builds successful environments for biotech startups and has
become the international model for co-working in the life sciences.
Also, discover how public-private partnerships fuel these destinations
and build the base for economic development as a part of this system,
and how universities and large institutions play a critical role. The
other Cambridge tour will stop at MIT’s Koch Institute featuring a panel
with Nobel prize winner Dr. Phillip A. Sharp, a world leader in
molecular biology and biochemistry; Dr. Angela Belcher, a leading
biological engineer, and Dr. Anne Deconinck, executive director of the
Koch Institute.

The development of Quincy Center into a medical and research area
is underway. The city has designated FoxRock Co. as the developer of
over 1M square-feet in the city and has plans for medical users with
lab/office space. Quincy has garnered more than $225M in private
investment for new residential units supported by $200M in State/Federal
funds solely for infrastructure to accommodate the new and exciting
development in the City of Presidents.

Visit Assembly Square to see an innovative model of mixed-use
development in Somerville, one of the area’s most creative and
exciting cities just over a mile from downtown Boston and Kendall Square
on public transit. Assembly Square, winner of Curbed Boston’s
“Neighborhood of the Year” award two years running, is anchored by
Partners HealthCare, the largest network of hospitals and physicians’
groups in the state, with 4,500 employees in a state-of-the-art
headquarters.

Tours will run from 11:30 a.m. to 4:30 p.m. and registration is $35.
Attendees should meet at the Boston Convention and Exhibition Center,
Room 160BC. Deadline to register is May 18. For more information and to
register, visit: https://bio.swoogo.com/biotours

About the Life Sciences Corridor

Formed in 2014, the Life Sciences Corridor is a partnership created by
the mayors of Boston, Cambridge, Quincy, Somerville and Braintree. The
Corridor is focused on promoting the robust life sciences sector along
the MBTA red line in the Greater Boston region. The initiative harnesses
the resources of the cities, individually and collectively, to foster
continued success in research, innovation and business development. For
more information, visit lifesciencescorridor.com.

Contacts

LaVoieHealthScience
Katie Gallagher, 617-374-8800 x109
kgallagher@lavoiehealthscience.com

Medical Tourism Global Markets and Figures 2018: Inbound and Outbound Figures for 165 Countries – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medical
Tourism Global Market and Figures 2018”
report has been added
to ResearchAndMarkets.com’s offering.

Medical Tourism Global Market and Figures 2018 examines the global
background and potential, as well as investigating inbound and outbound
figures for 165 countries.

Unlike other reports, this does not take quoted figures as gospel, but
analyses their reliability.

Report Summary:

  • Global medical tourism is increasing annually. What is changing
    rapidly is each country’s share of the total, and the type of medical
    tourist they are attracting
  • Countries thought of as suppliers of medical tourists-USA, China,
    Russia and Dubai are turning the tables and becoming major destinations
  • The report discusses the dynamics of medical tourism, providing
    insights into the supply chain, business models, products and the
    targeted consumer

Key Findings:

  • The global demand for medical tourism is changing
  • Some countries see increasing numbers but others struggle
  • This is a very fluid market
  • Some strategies and marketing are working well
  • This market is not just price driven

Reason to Buy:

  • Trying to keep up to date with the ever-changing medical tourism world
    in every country is like walking backwards up an escalator- stand
    still and you fall over
  • Every country and organisation needs to update and refine its medical
    tourism strategy and to do that they need to know the latest on which
    countries are doing well or badly, who goes there, the treatment they
    seek and why they go there
  • Every country and organisation needs to know what other countries and
    global groups are doing
  • This report is essential reading to any organisation serious about
    medical tourism, with background material suitable for both experts
    and newcomers

Key Topics Covered:

1. Overview

2. International Medical Tourism Figures

3. International Medical Tourism Market

4. Medical Tourism Customers

5. Medical Tourism Products And Services

6. Medical Tourism And Insurance

7. European Cross Border Healthcare

8. International Organisations

9. UK And Brexit And Healthcare

10. Countries Profiled

For more information about this report visit https://www.researchandmarkets.com/research/24xb5l/medical_tourism?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Medical
Tourism

Proteus Digital Health® Announces Digital Medicines Pipeline Development and Expansion into Oncology

REDWOOD CITY, Calif.–(BUSINESS WIRE)–#DigiMeds–Proteus Digital Health®, Inc. today announced that together with its
collaborators, the company has developed a pipeline of 31 digital
medicines for mental health, cardiovascular and metabolic conditions,
infectious diseases, and oncology.

Andrew Thompson, Chief Executive Officer of Proteus commented on why the
company is confidently investing to expand its pipeline. “Our extensive
clinical trial and commercial experience with digital medicines with
thousands of patients has been overwhelmingly positive. The products are
well accepted by consumers, secure, private, fully HIPAA compliant and
extraordinarily safe. More importantly, we have shown consistently that
patients who choose to use DigiMeds™ take them about 90% of the time,
compared to medication possession of 50% with regular drugs. Physicians
coach patients and properly titrate medicines at three times the rate
when they have accurate data on drug use and activities of daily life
that our solutions provide. This is more important than ever: on March
26, 2018 the Annals of Pharmacotherapy published a study estimating that
inappropriate drug use costs the U.S. $524.4 billion a year, about 16%
of total US healthcare spending. Wider use of digital medicines will
help many patients and will help save a lot of money.”

Proper use of medicines is especially important in the treatment of
mental health, where patients can be hospitalized if they do not
consistently use their drugs in the right dose. Proteus is working with
Otsuka Pharmaceutical Company to develop digital medicines for the
treatment of Bipolar, Schizophrenia and Major Depressive Disorder.
Otsuka received the first NDA approval for a digital medicine, ABILIFY
MYCITE® (aripiprazole tablets with sensor), in November 2017. Proteus
and Otsuka are investigating the development of additional digital
medicine products in mental health where there is the greatest patient
need, and assessing opportunities for regulatory registration.

In cardiovascular and metabolic conditions, Proteus has a panel of
15 digital medicines that can be prescribed to named patients in the
United States, prepared and delivered via specialty pharmacy services.
Health systems in the US have entered into master service agreements to
use the digital medicines, focusing on high-risk patients who are
failing drug therapy. Proteus has conducted several clinical studies
demonstrating the clinical and economic benefits of using digital
medicines to improve outcomes in these patients, including a successful
randomized control trial in patients with uncontrolled hypertension and
type 2 diabetes (J
Med Internet Res 2017;19(7):e246
).

In infectious disease, the company has seven digital medicines that are
being used in clinical studies to treat patients with TB, hepatitis C
and HIV. These programs are designed to demonstrate that digital
medicines effectively support expanded access to curative or life
sustaining drug therapies, ensuring excellent medication adherence with
high levels of patient autonomy and satisfaction. UC San Diego TB
researcher, Dr. Sara Browne, recently completed a randomized control
trial comparing digital medicines-enabled Wirelessly Observed Therapy
(WOT) to Directly Observed Therapy (DOT), finding that WOT detected 54%
more doses than DOT while freeing patients from onerous direct
observation requirements.

Proteus is developing a portfolio of digital medicines to help cancer
patients. These DigiMeds™ include oral oncology agents that require
complex dosing, as well as drugs intended to help alleviate side
effects, including opioid analgesics. An advisor in this initiative is
Dr. Linda Sutton, an Associate Professor of Medicine at the Duke
University School of Medicine.

“Proteus technology has the potential to improve the quality of cancer
care and make the work of cancer treatment teams timelier, more precise
and more effective,” said Dr. Sutton. “The explosion of therapeutic
options with new drugs, as well as new molecular and genetic tests, has
made oncology care increasingly complicated. We need the ability to
support patient use of drugs in the right dose, on the right
schedule, and ensure that these powerful medications are working as
intended. There is so much uncertainty when prescribing oral oncolytics
today. We send patients out of the clinic with prescriptions to fill and
take at home, and oncology teams are challenged to guide patients
through their treatment remotely. With digital oral chemotherapy drugs,
the patient’s oncologist will know with certainty when the patient took
his or her chemo. That puts the oncologist in a better position to
determine if subsequent problems are related to disease progression or
drug toxicity, and better able to assess drug efficacy.”

About Proteus Digital Health®

Proteus Digital Health is enabling a new category of pharmaceutical:
Digital Medicines. These offerings include widely used drugs, formulated
so they communicate when they have been swallowed; a wearable patch that
detects medicines and captures physiologic response; mobile applications
to support patient self-care and physician decision-making; and data
analytics to serve the needs of health system managers. The company has
more than 440 issued patents that protect this enabling technology, and
regulatory clearances in the U.S., European Union and China.

Proteus Digital Health is privately held by investors that include
Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®,
Novartis®, Otsuka, PepsiCo, and ON Semiconductor®.
Further information is available at: www.proteus.com.
Connect with us on Twitter @ProteusDH.

Proteus Digital Health® is a registered trademark owned by Proteus
Digital Health, Inc.. Abilify MyCite® is a registered trademark owned by
Otsuka Pharmaceutical Co. Ltd.

Contacts

Proteus Digital Health, Inc.
Emily Fox, +1 650-637-6240
Director
of Communications
efox@proteus.com